Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

BACKGROUND: Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a monoclonal antibody against interleukin-5 receptor α, which is expressed on human eosinophils. METHODS: In this randomized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Kuang, Fei Li, Legrand, Fanny, Makiya, Michelle, Ware, JeanAnne, Wetzler, Lauren, Brown, Thomas, Magee, Tamika, Piligian, Brent, Yoon, Pryscilla, Ellis, Jamie H., Sun, Xiaoping, Panch, Sandhya R., Powers, Astin, Alao, Hawwa, Kumar, Sheila, Quezado, Martha, Yan, Li, Lee, Nancy, Kolbeck, Roland, Newbold, Paul, Goldman, Mitchell, Fay, Michael P., Khoury, Paneez, Maric, Irina, Klion, Amy D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6557265/
https://ncbi.nlm.nih.gov/pubmed/30943337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1812185
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados